Free Trial

Aardvark Therapeutics (AARD) Stock Forecast & Price Target

Aardvark Therapeutics logo
$3.99 -0.21 (-5.00%)
Closing price 04:00 PM Eastern
Extended Trading
$4.16 +0.17 (+4.14%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aardvark Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
2
Hold
4
Buy
7

Based on 13 Wall Street analysts who have issued ratings for Aardvark Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 2 have given a sell rating, 4 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for AARD.

Consensus Price Target

$19.70
393.73% Upside
According to the 13 analysts' twelve-month price targets for Aardvark Therapeutics, the average price target is $19.70. The highest price target for AARD is $47.00, while the lowest price target for AARD is $3.00. The average price target represents a forecasted upside of 393.73% from the current price of $3.99.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for AARD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Aardvark Therapeutics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AARD Analyst Ratings Over Time

TypeCurrent Forecast
5/27/25 to 5/27/26
1 Month Ago
4/27/25 to 4/27/26
3 Months Ago
2/26/25 to 2/26/26
1 Year Ago
5/27/24 to 5/27/25
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
11 Buy rating(s)
4 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
2 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$19.70$22.60$32.64$31.25
Forecasted Upside393.73% Upside309.42% Upside161.09% Upside218.23% Upside
Consensus RatingHoldModerate BuyModerate BuyBuy

AARD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AARD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Aardvark Therapeutics Stock vs. The Competition

TypeAardvark TherapeuticsMedical CompaniesBroader Market
Consensus Rating Score
2.46
2.30
2.52
Consensus RatingHoldHoldModerate Buy
Predicted Upside369.05% Upside1,704.03% Upside15.04% Upside
News Sentiment Rating
Neutral News

See Recent AARD News
Neutral News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
5/15/2026
William Woods
Not Rated
Lower TargetBuy$8.00 ➝ $7.00+35.32%
5/15/2026
BTIG Research logo
BTIG Research
2 of 5 stars
DowngradeBuyHold
5/15/2026
Morgan Stanley logo
Morgan Stanley
3 of 5 stars
Michael Ulz
Michael Ulz
5 of 5 stars
Reiterated RatingEqual WeightUnderweight$7.00 ➝ $3.00-55.42%
5/13/2026 UpgradeSell (E+)Sell (D-)
3/2/2026DowngradeOutperformSector Perform$18.00 ➝ $6.00-51.96%
3/2/2026Lower TargetOutperform$35.00 ➝ $21.00+280.43%
3/2/2026Reiterated RatingBuyHold$24.00 ➝ $6.00-51.96%
3/2/2026Reiterated RatingBuyNeutral
1/12/2026Reiterated RatingStrong-Buy$47.00+229.36%
12/12/2025Initiated CoverageOutperform
11/14/2025 Reiterated RatingOverweight
10/1/2025Initiated CoverageBuy$33.00+148.31%
8/28/2025Lower TargetBuy$26.00 ➝ $25.00+189.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 05:00 PM ET.


AARD Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Aardvark Therapeutics is $19.70, with a high forecast of $47.00 and a low forecast of $3.00.

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aardvark Therapeutics in the last year. There are currently 2 sell ratings, 4 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AARD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AARD, but not buy additional shares or sell existing shares.

According to analysts, Aardvark Therapeutics's stock has a predicted upside of 393.73% based on their 12-month stock forecasts.

Over the previous 90 days, Aardvark Therapeutics's stock had 3 downgrades and 1 upgrade by analysts.

Aardvark Therapeutics has been rated by research analysts at B. Riley Financial, BTIG Research, HC Wainwright, Morgan Stanley, Oppenheimer, Royal Bank Of Canada, Stifel Nicolaus, and Weiss Ratings in the past 90 days.

Analysts like Aardvark Therapeutics more than other "medical" companies. The consensus rating score for Aardvark Therapeutics is 2.46 while the average consensus rating score for "medical" companies is 2.30. Learn more on how AARD compares to other companies.


This page (NASDAQ:AARD) was last updated on 5/27/2026 by MarketBeat.com Staff.
From Our Partners